0.00Open0.00Pre Close0 Volume0 Open Interest70.00Strike Price0.00Turnover0.00%IV-38.93%PremiumOct 11, 2024Expiry Date44.63Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.57Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Abbott Laboratories Stock Discussion
Gapping up
$Royal Philips (PHG.US)$ experienced a significant boost of 10.6% after the company reported robust second-quarter earnings, attributing much of their success to cost-saving measures, including workforce reductions, and a substantial insurance payout related to liability claims.
$Tesla (TSLA.US)$ 's shares advanced by 1.9% following an endorsement by Morgan Stanley analyst Adam Jonas, naming it the top ...
The season started off last Friday with $JPMorgan (JPM.US)$ , $Wells Fargo & Co (WFC.US)$ , and $Wells Fargo & Co (WFC.US)$ sharing their numbers. They all did bett...
The stock has break below the support 101.56. Looks bearish. Next support is 100.64.
Bearish engulfing pattern appears in the chart. This stock has turned bearish. Next support is 101.56.
Gapping up
$United Airlines (UAL.US)$ stock rose 5.2% after the carrier forecast stronger-than-expected earnings in the current quarter and reported a narrower-than-expected loss in the first quarter, buoyed by robust demand for travel.
$Abbott Laboratories (ABT.US)$ stock increased by 1.6% after the company surpassed quarterly profit expectations and raised the lower end of its earnings forecast, with strong dem...
Introduction
On April 17th, before the US stock market opened, Abbott (NYSE: ABT) will hold a conference call to announce its financial results for the first quarter of 2024. As a global leader in healthcare, Abbott's performance has been steadily improving in recent years, especially benefiting from the COVID-19 pandemic. According to Bloomberg data, the follow...
No comment yet